Radionetics Oncology
Chetan Lathia is a seasoned professional in regulatory affairs, clinical pharmacology, and nonclinical development with extensive experience in the pharmaceutical industry. Currently serving as SVP at Radionetics Oncology, Chetan leads regulatory strategy and engages with FDA and global agencies to facilitate drug development. Prior to this role, Chetan held senior positions at BioXcel Therapeutics as Senior VP, Intarcia Therapeutics as Vice President, and Alexion Pharmaceuticals as Executive Director, where responsibilities included managing clinical pharmacology, regulatory affairs, and pharmacometrics. Chetan's career began at Bayer Pharmaceuticals and Parke-Davis, contributing to oncology and cardiovascular research, and has a strong educational background with a B.S. in Pharmacy and a Ph.D. in Clinical Pharmacology/Pharmacokinetics from reputable institutions.
This person is not in any teams
This person is not in any offices
Radionetics Oncology
Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company’s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.